life scienc tool diagnost
labcorp america lh
ep profit rais est
ep exce consensu lh ep beat
weaker revenu off-set better profit factor line
neg impact ep lh narrow ep guidanc
midpoint maintain vs consensu
rais ep reflect beat
price move higher view
lcd rev/req improv profit prevail total revenu slightli
reflect contract shift divestitur bp
fx bp off-set organ growth lcd
declin vs estimate essenti line fell organ
basi incl pama bp organ volum also fall
sequenti deterior note bp headwind
contract calendar shift revenue/acc
meaning better plan cdd larg line org
encouragingli post ttm btb estimate ebit
margin declin bp acquisit mix pama reserv stand
million cf million help fund share repurchas
share may ebb lh share ytd vs latest
print like enough stock move meaning higher
particularli follow strong report competitor quest diagnost
earlier week acknowledg known headwind contract
shift organ volum declin disappoint await
call detail pars impact well contract win
said maintain posit bia continu highlight
diversif strategi cdd organ growth btb
sequenti improv demonstr healthi underli
cro fundament focu call contract roll off/pama
reflect guid quarterli cro btb prospect lead lab
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
labcorp provid diagnost test inform servic
labcorp america lh
price jul rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
better fundament perform sentiment could drive upsid
target price blue sky scenario lh
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
lh
labcorp america lh
compani mention price
labcorp america lh outperform tp
